Navigation Links
Mayo Clinic study finds two genes predict outcome for breast cancer patients

Mayo Clinic researchers report that the expression of two novel genes within the tumors of women with early stage breast cancer may allow identification of women who are and are not at risk for early relapse or cancer-related death. Results of the study are published in the April 1 issue of Clinical Cancer Research.

"The HOXB13 and IL17BR gene profile was previously discovered as a potential marker of relapse in hormone-receptor positive breast cancer treated with tamoxifen," says Matthew Goetz, M.D., who co-led the project with James Ingle, M.D. and Fergus Couch, Ph.D. "Our new study shows that the marker is only useful for identifying women with a higher risk in the setting of lymph node-negative breast cancer."

The study, which was conducted by researchers at Mayo Clinic, Harvard Medical School and Arcturus Bioscience, tested whether the expression levels of two genes within women with early stage breast cancer affected the outcomes of women with estrogen receptor-positive breast cancer. The research team examined tissue from 206 postmenopausal women enrolled in a prospective study conducted by the North Central Cancer Treatment Group (NCCTG). They tested the level of gene expression of HOXB13 and IL17BR from paraffin-embedded tumors and found that the 2-gene expression ratio was an independent marker of early breast cancer relapse or death in lymph node-negative breast cancer.

"We believe that these findings are clinically important and corroborate the accumulating laboratory data which suggests that the HOXB13 gene is critically involved in breast cancer metastases," says Dr. Goetz. "Further research is needed to determine whether more aggressive or additional treatments will improve the outcomes of women identified to be at high risk by means of this marker."

Breast cancer is diagnosed in approximately one million women each year, and claims the lives of over 40,000 in the United States. More than two-thirds of all breast
'"/>

Source:Mayo Clinic


Page: 1 2

Related biology news :

1. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
2. Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show Its Snot
3. Clinical trial to test stem cell approach for children with brain injury
4. Mayo Clinic collaboration discovers protein amplifies DNA injury signals
5. Mayo Clinic researchers challenge sepsis theory
6. Mayo Clinic researchers discover cancer cells may move via wave stimulation
7. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
8. Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug
9. Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits
10. Mayo Clinic: Gene expression profiling not quite perfected in predicting lung cancer prognosis
11. Bioartificial kidney under study at MCG
Post Your Comments:
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... In the five months since passage of the ... of research-related awards have been made, supporting important scientific ... increase in basic research funding in American history - ... scientific research and education projects, while $3.5 billion is ...
... 30, 2009) A team of 80 researchers from ... Shifting Sands: Environmental and Cultural Change in Maryland,s Coastal ... barrier islands making up Maryland,s Atlantic coastline. Published ... the history, setting, context and ecology of these waterways, ...
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2
(Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... Ill. (PRWEB) October 01, 2014 The ... $9,956,011 to Southern Illinois University Edwardsville as part of ... (TAACCCT) initiative. The funding is co-administered by the Department ... Joe Biden, Secretary of Labor Thomas E. Perez and ... $450 million in job-driven training grants to nearly 270 ...
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... the Largest Sales Teams Promoting a 5-ASA ... 26 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: ... a co-promotion agreement with,TAP Pharmaceutical Products Inc. ... the induction of remission in patients with,active, ...
... March 26 Thomas W. Burke, MD, Executive ... M.D. Anderson,Cancer Center, has been elected the 40th ... the organization,s 39th Annual Meeting,held March 9-12, 2008 ... undergraduate and medical degrees from Tulane,University in New ...
Cached Biology Technology:Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Biology Products: